| Population | Most Common Organisms | Key Notes |
|---|---|---|
| Adults (non-gonococcal) | Staphylococcus aureus (60–70%), Streptococcus spp. (15–20%) | MRSA prevalence increasing, consider empiric vancomycin. GNRs in elderly, immunocompromised, IVDU. |
| Young sexually active adults | Neisseria gonorrhoeae | Most common cause in sexually active young adults. Migratory polyarthralgia → mono/oligoarthritis + tenosynovitis + skin lesions (pustular). Blood/synovial cultures often negative, send NAAT. |
| Children <5 years | S. aureus, Kingella kingae, Group A Strep | Kingella often culture-negative, request PCR/16S rRNA. H. influenzae now rare (vaccination). |
| IVDU | S. aureus, Pseudomonas, Serratia | Unusual joints (sacroiliac, sternoclavicular). Consider GNR coverage. |
| Prosthetic joint | S. aureus, coagulase-negative Staph, Cutibacterium acnes | Early (<3 months): aggressive organisms. Late (>12 months): low-virulence organisms (CoNS, C. acnes). Hold cultures ≥14 days for slow-growers. |
| Animal/human bites | Pasteurella multocida (cat), Eikenella corrodens (human), polymicrobial | Amoxicillin-clavulanate for bite wounds near joints. If joint penetrated, treat as septic arthritis. |
| Parameter | Normal | Non-inflammatory | Inflammatory (Gout/RA) | Septic |
|---|---|---|---|---|
| Appearance | Clear, colorless | Clear, yellow | Translucent–opaque, yellow | Opaque, purulent |
| WBC (/μL) | <200 | 200–2,000 | 2,000–50,000 | >50,000 (often >100K) |
| PMN % | <25% | <25% | 50–70% | >90% |
| Gram stain | Negative | Negative | Negative | Positive in 50–75% |
| Culture | Negative | Negative | Negative | Positive in 70–90% |
| Crystals | None | None | MSU (gout) or CPPD | Usually none (but coexistence possible) |
| Test | Rationale |
|---|---|
| Synovial fluid Gram stain & culture | Gold standard. Positive in ~70–90% for non-gonococcal. Only ~25% positive for gonococcal. Send in blood culture bottles to improve yield. |
| Synovial fluid crystal analysis | Rule out gout (negatively birefringent MSU) and pseudogout (weakly positive CPPD). Remember: crystals + infection can coexist. |
| Blood cultures (×2 sets) | Positive in 40–50% of non-gonococcal septic arthritis. Essential for tailoring therapy. |
| CBC, CRP, ESR | WBC, CRP elevated in most cases. CRP >100 mg/L has high sensitivity. ESR less specific. Useful for monitoring treatment response. |
| Gonococcal NAAT | Urethral/cervical/pharyngeal/rectal NAAT if disseminated gonococcal infection (DGI) suspected. Synovial fluid NAAT increasingly available. |
| X-ray (affected joint) | Often normal early. Soft tissue swelling, joint effusion. Late: joint space narrowing, erosions, periosteal reaction. Baseline for comparison. |
| Ultrasound | Detect effusion (especially hip, difficult to examine clinically). Guide arthrocentesis. Rapidly available at bedside. |
| MRI | Best imaging for complications: adjacent osteomyelitis, soft tissue abscess, synovial enhancement. Order if poor response to treatment. |
| Criteria | Points |
|---|---|
| Non-weight-bearing on affected side | 1 |
| Fever >38.5°C | 1 |
| WBC >12,000/μL | 1 |
| ESR >40 mm/hr | 1 |
0 criteria: <0.2% risk • 1: 3% • 2: 40% • 3: 93% • 4: 99% probability of septic arthritis. CRP >20 mg/L added as 5th criterion in modified Kocher.
| Method | When to Use | Key Points |
|---|---|---|
| Serial arthrocentesis (needle aspiration) | First-line for most accessible joints (knee, ankle, wrist, elbow) | Aspirate to dryness daily until effusion resolves. Monitor WBC trend, should decrease with effective treatment. Simple, bedside, repeatable. |
| Arthroscopic washout | Failed serial aspiration, loculated collection, shoulder | Better visualization, more thorough lavage. Can break adhesions/loculations. Preferred for shoulder (difficult to aspirate completely). |
| Open arthrotomy | Hip (always), failed arthroscopy, prosthetic joint, pediatric | Hip joint is deep and difficult to drain percutaneously, open surgical drainage is standard for septic hip. Also needed if hardware present or tissue necrosis. |
| Scenario | Empiric Regimen | Duration | Notes |
|---|---|---|---|
| Native joint (typical) | Vancomycin 15–20 mg/kg IV q8–12h | 2–4 weeks total (IV → PO step-down) | Covers MRSA + MSSA. Add ceftriaxone 2g IV daily if GNR suspected (elderly, immunocompromised, IVDU). De-escalate by culture. |
| GNR risk factors (elderly, IVDU, immunocompromised) | Vancomycin + Ceftriaxone 2g IV daily or Cefepime 2g IV q8h | 2–4 weeks | Cefepime if Pseudomonas risk (IVDU, recent hospitalization). Narrow by culture & sensitivity. |
| Disseminated gonococcal infection | Ceftriaxone 1g IV daily | 7–14 days (switch to PO after improvement) | Treat until clinically improved (usually 24–48h IV) then step down to PO cefixime or azithromycin. Treat concomitant chlamydia (azithromycin 1g or doxycycline). Test + treat sexual partners. |
| Prosthetic joint infection (acute) | Vancomycin + Cefepime or Meropenem | 6 weeks IV + chronic suppressive PO | ID + Orthopedics co-management. Options: DAIR (debridement, antibiotics, implant retention) if early (<30 days) and stable implant. Otherwise: 1-stage or 2-stage exchange arthroplasty. |
| Drug (Brand) | Mechanism | Dosing | Key Considerations |
|---|---|---|---|
| Vancomycin (Vancocin) | Glycopeptide, inhibits cell wall synthesis by binding D-Ala-D-Ala | 15–20 mg/kg IV q8–12h Target AUC/MIC 400–600 | Empiric MRSA coverage. Monitor trough or AUC. Nephrotoxic, monitor SCr. Red man syndrome with rapid infusion (rate-related, not allergy). Good synovial fluid penetration. |
| Ceftriaxone (Rocephin) | 3rd-gen cephalosporin, inhibits PBPs | 2g IV q24h | GNR coverage + gonococcal coverage. Once-daily dosing (long half-life). Do not use in neonates with bilirubin issues. Good bone/joint penetration. |
| Cefazolin (Ancef) | 1st-gen cephalosporin | 2g IV q8h | Step-down from vancomycin once MSSA confirmed. Excellent bone penetration. Can transition to PO cephalexin or dicloxacillin. |
| Nafcillin/Oxacillin | Anti-staphylococcal penicillin | 2g IV q4h | Gold standard for MSSA. Excellent bone/joint penetration. Interstitial nephritis risk. Alternative: cefazolin (easier dosing). |
| Cefepime (Maxipime) | 4th-gen cephalosporin | 2g IV q8h | Pseudomonas coverage + GNR. Use when Pseudomonas risk (IVDU, nosocomial). CNS toxicity at high doses/renal impairment. |
| TMP-SMX (Bactrim) | Folate synthesis inhibitor | DS 1–2 tabs PO BID | Oral MRSA step-down option. Good bioavailability. Monitor K⁺ (hyperkalemia risk). Not for strep coverage (unreliable). |